Exact Mass: 305.0051352
Exact Mass Matches: 305.0051352
Found 34 metabolites which its exact mass value is equals to given mass value 305.0051352
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
2-[5-(3,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl]aniline
3-Bromo-N-(tert-butyl)-5-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
ETHYL 3-(5-BROMO-2-METHYL-4-NITRO-1H-IMIDAZOL-1-YL)PROPANOATE
C9H12BrN3O4 (305.00111319999996)
n-t-butyl 3-bromo-4-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
7-BROMO-1,2,3,4-TETRAHYDRO-ACRIDINE-9-CARBOXYLICACID
2-Bromo-N-pentylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
ETHYL 2-CHLORO-2-(2-(4-CHLORO-2-NITROPHENYL)HYDRAZONO)ACETATE
C10H9Cl2N3O4 (304.99700939999997)
3-(6-Bromopyridin-2-yl)-4-methyl-benzoic acid methyl ester
[2-(5-BROMO-THIOPHEN-2-YL)-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
C11H16BrNO2S (305.00850560000003)
5-bromo-N-(tert-butyl)-2-Methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
3-Bromo-N-butyl-5-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
3-Bromo-N-(tert-butyl)-N-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
4-Bromo-N-(tert-butyl)-3-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
3-bromo-N,N-diethyl-4-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
3-Bromo-N,N-diethyl-5-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
4-Bromo-N,N-diethyl-3-methylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
N-BUTYL 3-BROMO-4-METHYLBENZENESULFONAMIDE
C11H16BrNO2S (305.00850560000003)
3-Bromo-N-pentylbenzenesulfonamide
C11H16BrNO2S (305.00850560000003)
7-Nitro-9-oxo-9H-fluorene-2-sulfonic acid
C13H7NO6S (304.99940820000006)
Taminadenant
Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response[1][2].